Almirall's uncertainty on 2020 earnings hits share price

24 February 2020

The Coronavirus hit markets on Monday morning, with the uncertainty around its impact doing damage to the share prices of many pharma and biotech companies.

But a company that had a particularly bad morning in the stock market was Almirall (ALM: MC), the Spanish dermatology specialist, which presented its full-year 2019 financial results and its outlook for 2020. The latter is likely to be responsible for the 3% reduction in the firm’s share price as trading entered its final third.

The annual revenue figure, of 908.4 million euros ($983 million) showed healthy growth of 12% compared to 2018, and earnings before interest, taxes, depreciation and amortization (EBITDA) jumped by 45% to 304.2 million euros.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK